The group considers national controlled drugs governance in England.
It provides collaboration, consistency and assurance to government by:
- sharing intelligence
- highlighting good practice and areas of concern
- reporting on the impact of controlled drugs arrangements
Membership of the national group
- Care Quality Commission
- Department of Health
- General Medical Council
- General Pharmaceutical Council
- Health and Social Care Information Centre
- Her Majesty's Inspectorate of Prisons for England and Wales
- Medicines Advice (Medicines and Prescribing Centre) National Institute for Health and Care Excellence
- Medicines and Healthcare products Regulatory Agency
- Ministry of Defence
- National Police Chiefs’ Council
- NHS Counter Fraud Authority
- NHS England (including Health and Justice Commissioning)
- The Home Office
- UK Anti-doping
- Veterinary Medicines Directorate
Four sub-groups provide expert advice to the national group and issue newsletters. They cover these aspects of controlled drugs:
- theft and fraud
- monitoring prescribing
- safe prescribing, dispensing and administration
- policy and operational issues
Subgroup members are from the national group as well as invited specialists.
These newsletters report the group’s findings. They signpost you to guidance and share examples of good practice and local initiatives for information. Providers may follow different approaches according to their local needs..
This gives an example of how a specific organisation responded locally to safety concerns around Alfentanil.
Previous newsletters and guidance
See our earlier newsletters and guidance on safety incidents and checklists on the National Archives.